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Background: Obesity is associated with development of the cardiorenal metabolic syndrome, which is a
constellation of risk factors, such as insulin resistance, inflammatory response, dyslipidemia, and high blood pressure
that predispose affected individuals to well-characterized medical conditions such as diabetes, cardiovascular and
kidney chronic disease. The study was designed to establish relationship between metabolic and inflammatory
disorder, renal sodium retention and enhanced blood pressure in a group of obese subjects compared with
age-matched, lean volunteers.
Methods: The study was performed after 14 h overnight fast after and before OGTT in 13 lean (BMI 22.92 ± 2.03 kg/m2)
and, 27 obese (BMI 36.15 ± 3.84 kg/m2) volunteers. Assessment of HOMA-IR and QUICKI index were calculated and
circulating concentrations of TNF-α, IL-6 and C-reactive protein, measured by immunoassay.
Results: The study shows that a hyperinsulinemic (HI: 10.85 ± 4.09 μg/ml) subgroup of well-characterized metabolic
syndrome bearers-obese subjects show higher glycemic and elevated blood pressure levels when compared to lean
and normoinsulinemic (NI: 5.51 ± 1.18 μg/ml, P < 0.027) subjects. Here, the combination of hyperinsulinemia, higher
HOMA-IR (HI: 2.19 ± 0.70 (n = 12) vs. LS: 0.83 ± 0.23 (n = 12) and NI: 0.98 ± 0.22 (n = 15), P < 0.0001) associated with
lower QUICKI in HI obese when compared with LS and NI volunteers (P < 0.0001), suggests the occurrence of
insulin resistance and a defect in insulin-stimulated peripheral action. Otherwise, the adiponectin measured in basal
period was significantly enhanced in NI subjects when compared to HI groups (P < 0.04). The report also showed a
similar insulin-mediated reduction of post-proximal urinary sodium excretion in lean (LS: 9.41 ± 0.68% vs. 6.38 ± 0.92%,
P = 0.086), and normoinsulinemic (NI: 8.41 ± 0.72% vs. 5.66 ± 0.53%, P = 0.0025) and hyperinsulinemic obese subjects
(HI: 8.82 ± 0.98% vs. 6.32 ± 0.67%, P = 0.0264), after oral glucose load, despite elevated insulinemic levels in
hyperinsulinemic obeses.
Conclusion: In conclusion, this study highlights the importance of adiponectin levels and dysfunctional inflammatory
modulation associated with hyperinsulinemia and peripheral insulin resistance, high blood pressure, and renal
dysfunction in a particular subgroup of obeses.
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Obesity, a public health problem of the first order for in-
dustrialized and non-industrialized countries dramatically
cause a reduction in overall life expectancy [1]. The
prevalence of obesity in different populations is related
to environmental factors, such as reduced physical activity
and diet, mainly. Nowadays, with growing industrialization
and modern lifestyle, the access to high fat and carbohy-
drate diets has changed the eating habits of the population.
These aspects interact with genetic factors, which may ex-
plain the excessive body fat throughout the world [2]. Over-
weight and obesity are related to increased prevalence
of cardiovascular disease, dyslipidemia, type 2 diabetes
mellitus, neurological disease, chronic kidney disease
and cancers [3-5]. Obesity appears to be an important
factor in elevating blood pressure in many prehyperten-
sive individuals since studies have shown that high
blood pressure is more prevalent in obese than in non-
obese subjects [2-4]. In this way, experimental studies
have demonstrated that weight gain, even over a period
of a few weeks, consistently elevates blood pressure and
weight loss decreases blood pressure independent of
changes in sodium intake. Recently, study in our labora-
tory has demonstrated that podocyte injury in parallel
with proteinuria and evidence of epidermal mesenchy-
mal transition transformation are associated with long-
term loss of kidney function and renal sodium and
water retention in obesity induced by high-fat diet in-
take in rats [5]. However, establishing cause-and-effect
relations has been hampered by the lack of suitable ani-
mal models that mimic obesity induced hypertension in
humans and that allow sequential changes in renal,
endocrine, and cardiovascular function to be monitored
during the development of obesity. Although this asso-
ciation between obesity and hypertension is widely rec-
ognized, the mechanisms responsible for weight-related
changes in blood pressure have not been elucidated.
Also, sparse reports that deal with the relationship be-
tween inflammatory response, plasma insulin and cyto-
kines levels and blood pressure in obese subjects are
known to revision see ref. [6,7]. Additionally, overweight
and obesity are associated with development of the car-
diorenal metabolic syndrome which is a constellation of
risk factors, such as insulin resistance, dyslipidemia, and
high blood pressure that predispose affected individuals
to well-characterized medical conditions such as dia-
betes, cardiovascular and kidney chronic disease [7-14].
However, the pathophysiological mechanisms and humoral
factors involved in obesity and that lead to sodium reten-
tion and higher blood pressure in obeses are still unclear.
Therefore, the current study was designed to establish rela-
tionship between metabolic and inflammatory disorder,
renal sodium handling disorder and enhanced blood
pressure in a group of obese subjects compared with age-matched, lean volunteers. To address the different parame-
ters among lean and obese groups, the study was per-
formed by examining oral glucose tolerance test, HOMA-
IR and QUICKI index, renal tubule sodium handling and
plasmatic inflammatory cytokine markers.
Subjects and methods
Subjects
Forty normotensive volunteers aged 18–50 years were en-
rolled in the study and divided into two subject groups: (1)
13 lean (LS, BMI 22.92 ± 2.03) and, (2) 27 outpatient obese
(OS, BMI 36.15 ± 3.84) volunteers. Body mass index (BMI)
was calculated based on ratio between body mass (in kg)
and squared height (in meters) [weight (kg)/height (m2)].
On the basis of fasting plasma insulin and glucose lev-
els homeostasis model assessment of insulin resistance
(HOMA-IR), two distinct obese subgroup profiles were
identified by HOMA-IR z-score, and subdivided in (3) 15
normoinsulinemic obese (NI, BMI 35.25 ± 3.80 kg/m2)
and (4) 12 hyperinsulinemic obese (HI, BMI 37.05 ±
3.88 kg/m2). The present study evaluated the body com-
position measurements using bioelectrical impedance
analysis and the energy expenditure was assessed by
continuous indirect calorimetry performed with a calorim-
eter (SensorMedics Corp., Anaheim, California, USA). The
characteristics of these experimental groups are presented
in Table 1. A complete medical examination was carried
out to exclude arterial hypertension (their office systolic
and diastolic pressure should be lower than 140 and
90 mmHg, respectively, when measured on at least three
occasions) and personal history of diabetes mellitus (fasting
glucose less than 5 mM), or chronic renal, liver and others
endocrine diseases. Both lean and obese subjects had nega-
tive first degree familiar histories of diabetes mellitus and
arterial hypertension. None of the volunteers had shown re-
cent changes in the body mass or dietary habits, and they
were asked to continue their normal activities throughout
the study. The female participants were studied during the
follicular phase of the menstrual cycle. Other exclusion’s
criteria for all the subjects were: steroidal and non steroidal
anti-inflammatory therapies, hormonal substitutive or
contraceptive therapy, hormonal therapy for any thyroid
dysfunctions, drugs or alcohol abuse, smoking and mental
disability. The protocol (#1221/2009) was approved by In-
stitutional Review and Ethics Committee of Medical Sci-
ence School at Campinas State University and all subjects
gave their consent to participate of the study, which was
conducted according to the guidelines for human experi-
mentation established by the Declaration of Helsinki (2013)
and Brazilian laws on this matter.
Experimental design and methods
The studies were performed after 14 h overnight fast du-
ring which water ingestion was permitted [8-10,15-17]. A
Table 1 Subject’s general clinical characteristics for obese and lean groups
Control n Normoinsulinemic n Hyperinsulinemic n p p1 p2 p3
(LS) (NI) (HI) LS vs. NI LS vs. HI NI vs. HI
M/F* 4/9 13 2/13 15 5/7 12 ns - - -
Age (years) 33 ± 12 13 29 ± 7 15 29 ± 8 12 ns ns ns ns
Body mass (Kg) 63.71 ± 8.98 13 95.67 ± 12.78 15 103.464 ± 12.89 12 0.0001 0.0001 0.0001 ns
Height (m) 1.66 ± 0.10 13 1.63 ± 0.09 15 1.69 ± 0.09 12 ns ns ns ns
BMI (kg/m2) 22.92 ± 2.03 13 35.25 ± 3.80 15 37.05 ± 3.88 12 0.0001 0.000 0.0001 ns
Fat mass (kg) 18.66 ± 3.98 13 36.70 ± 7.15 15 40.80 ± 9.24 12 0.0001 0.0001 0.0001 ns
Lean mass (kg) 41.49 ± 6.02 13 57.22 ± 8.02 15 63.76 ± 10.12 12 0.0001 0.0001 0.0001 ns
Body water (%) 48.77 ± 4.98 13 41.34 ± 5.16 15 42.04 ± 4.72 12 0.006 0.004 0.008 ns
Basal metabolic rate (kcal) 1261.3 ± 183.53 13 1740 ± 244.07 15 1938.45 ± 307.62 12 0.0001 0.000 0.0001 ns
M/F male/female; BMI body mass index; Values are means ± DP; P values for comparison between groups by non-parametric analysis of Kruskal Wallis; *P values
for comparison between groups by non-parametric analysis descriptive of Chi-Square; P, comparing all groups. P1, P2 and P3 comparison between groups.
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to all subjects 14 hours before the renal tests. At 8:00 a.m.,
each subject was asked to empty his bladder and to dis-
card the urine. Immediately thereafter, diuresis was in-
duced by an oral loading equivalent to 20 ml of tap water/
kg body lean mass given between 8:00 and 8:45 h a.m.
The subjects rested comfortably in the sitting position
throughout the study and stood only to urine avoid. The
urinary volume losses were replaced with drinking tap
water every hour from 9:00 to 11:00 h a.m. Oral glucose
tolerance test (OGTT) consisting of a 75 g glucose load as
a 22% solution in water was performed concomitantly
with renal tests in both lean and obese subjects. Venous
blood was sampled at 0, 30, 45, 60, 90 and 120 minutes
for determination of glucose and insulin plasma levels.
For each subject, the following parameters were deter-
mined: blood pressure measured by a appropriated mer-
cury cuff, using a stethoscope placed over the brachial
artery for auscultation of pulse, according to the Task
Force Report on High Blood Pressure (NHBPEP, 1996),
BMI percentile, as well as serum concentrations of glu-
cose, insulin, cholesterol total, triacylglycerol, high-density
(HDL-cholesterol) low-density (LDL-cholesterol) and very
low-density (VLDL-cholesterol) lipoproteins cholesterol.
On the basis of fasting plasma insulin and glucose levels
homeostasis model, assessment of insulin resistance
(HOMA-IR) [11,18] and quantitative insulin-sensitivity
check (QUICKI) [12,19] indexes were calculated. HOMA-
IR and QUICKI were calculated according to the formulae:
HOMA-IR = fasting insulin (μU/ml) × fasting blood glu-
cose (mM)/22.5 and, QUICKI = 1/[log fasting insulin
(μU/ml) + log fasting blood glucose (mg/100 ml)], i.e.
1/[log fasting insulin (μU/ml) + log fasting blood glu-
cose (mM) × 18.182].
Creatinine and lithium clearance
The creatinine clearance (CCr) used to estimate the
glomerular filtration rate and the lithium clearance (CLi)used to estimate the sodium output from the proximal
tubule were calculated by standard formulas (U.V)/P)
where, U is the urinary creatinine and lithium concen-
trations, V is the urinary flow and P is the creatinine and
lithium plasma levels. Fractional sodium (FENa) and po-
tassium (FEK) excretion were calculated as CNa/CCr ×
100 and CEK/CFK × 100, respectively, where CNa is so-
dium clearance, CEK is potassium clearance, CCr is cre-
atinine clearance and CFK is filtered load potassium. The
fractional proximal (FEPNa) and post-proximal (FEPPNa)
sodium excretion were calculated as CLi/CCr × 100 and
CNa/CLi × 100, respectively [5,7,13,14,20-22].
Biochemical analysis
Plasma and urine sodium, potassium and lithium concen-
trations were measured by flame photometry (Micronal,
B262, São Paulo, Brazil), while creatinine concentrations
were determined spectrophotometrically (Instruments
Laboratory, Genesys V, USA). The Glucose Analyzer
YSI 2300 measured plasma glucose. Plasma concentra-
tions of insulin and C-peptide were measured by im-
munoassay (Millipore, Billerica, USA, with sensibility of
1μU/ml; and 0,05 ng/ml, respectively). The HDL and
LDL-cholesterol and, Triglyceride levels were also mea-
sured using enzyme immunoassay kits with a Modular
Analytic P Biochemistry Analyzer (Roche®) according to
the manufacturers' protocols. The cytokines were mea-
sured by immunoassay (adiponectin, Millipore, Billerica,
USA, sensibility 0,155 ng/ml; IL-6 R&D SYSTEMS®,
Minneapolis, USA, sensibility 0,039 pg/ml; leptin Millipore,
Billerica, USA, sensibility 0,195 ng/ml; TNF-α R&D SYS-
TEMS®, Minneapolis, USA; CRP DIAsource ImmunoAs-
says S.A, Louvain-la-Neuv, Belgium, sensibility 10 ng/ml).
Data presentation and statistics
All analyses were performed using SPSS (SPSS version
17.0). Data obtained from this study are expressed as the
mean ± SD or median and quartile deviation when
Figure 1 Representation of HOMA-IR in control (LS, n = 12) and
obese normoinsulinemic (NI, n = 15) and hyperinsulinemic (HI,
n = 12) subgroups. Data are expressed as median and quartile
deviation. The level of significance was set at **P≤ 0.001 versus LS
and NI (non-parametric analysis by Kruskal-Wallis test).
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analysis of the correlations of residues between the
model and the samples. The integrated glucose and insu-
lin secretion, i.e., the total area under curve (tAUC, mg/
ml/120 min and μU/ml/120 min, respectively) was cal-
culated by the trapezoidal method and we have used it
to establish the statistical difference between the lean
and subgroups of obese subject. Statistical analyses were
performed using non-parametric analysis by Kruskal-
Wallis test or Student t-test when appropriated from
GraphPad Prism 5.01 (GraphPad Software, Inc., USA).
Comparisons involving only two means within or be-
tween groups were carried out using a Student t-test.
We also analyzed independent factors related to systolic
blood pressure, body constitution and HOMA-IR index
values with multiple linear regression analysis. The level
of significance was set at P ≤ 0.05.
Results
Subjects characteristics
The characteristics of the all groups included in this
study are presented in Table 1. The three groups were
well matched for age. The mean age of the lean and
obese subjects was respectively, 33 ± 12 and 29 ±
7.5 years (NI, 29 ± 7.0; HI, 29 ± 8.0). Considering the
gender distribution, 44.4% of LS and 35% of OS were
male. On the basis of fasting plasma insulin and glu-
cose levels homeostasis model assessment of insulin
resistance (HOMA-IR), two distinct obese subgroup
profiles were identified by HOMA-IR z-score, and sub-
divided in normoinsulinemic obese and hyperinsuline-
mic obese volunteers (Figure 1). The mean HOMA-IR
index value were significantly higher in HI obese sub-
group when compared to LS and NI [HI: 2.19 ± 0.70
(n = 12) vs. LS: 0.83 ± 0.23 (n = 12) and NI: 0.98 ± 0.22
(n = 15), P < 0.0001]. The BMI differed significantly
(P < 0.0001) between LS (22.92 ± 2.03) and both nor-
moinsulinemic (35.25 ± 3.80 kg/m2) and hyperinsuline-
mic (37.05 ± 3.88 kg/m2) obese subjects (Table 1).
Mean lean mass (kg), fat mass (kg), percentual water
body constitution (%) and basal metabolic rate (kcal)
were significantly higher in both obese subgroups
when compared to LS values (Table 1). There were
no significant differences between the plasmatic values
to triglyceride, cholesterol, HDL-cholesterol total,
LDL-cholesterol and very-low density lipoprotein from
the LS group compared with OS subgroups (Table 2).
Additionally, as can be seen in Figure 2, the basal sys-
tolic blood pressure (in mmHg) from HI subjects
(130.7 ± 4.71) was significantly higher than from LS
(114.8 ± 16.6, P < 0.002) and NI (122.7 ± 12.3, P <
0.024) volunteers while the diastolic blood pressure
was different in NI subgroup (84.1 ± 8.4) when com-
pared to LS subjects (73.1 ± 12.4) (P < 0.031).Fasting glucose and insulin levels and oral glucose
tolerance test (OGTT)
The HI subgroup showed higher basal plasmatic insulin
and C peptide levels after overnight fasting (Insulin:
10.85 ± 4.09 μg/ml and C peptide: 1.37 ± 0.59 ng/ml),
when compared to the LS (Insulin: 4.25 ± 0.86 μg/ml
and C peptide: 0.774 ± 0.12 ng/ml, P < 0.0001) and NI
(Insulin: 5.51 ± 1.18 μg/ml and C peptide: 1.13 ± 0.82 ng/
ml, P < 0.027) groups (Figure 3). The fasting glucose
plasma level was significantly different only when obese
HI and NI were compared (P < 0.024). Otherwise, the HI
group achieved significantly higher plasma glucose con-
centrations than the LS and NI groups at 30, 60, 90 and
120 minutes, when analyzed the post-absorptive plasma
glucose levels after glucose oral loading. Thus, the incre-
mental total area under the curve (tAUC) to glucose
(Figure 3A) and insulin (Figure 3B) in HI was significantly
higher (P < 0.001) when compared to the LS and NI obese
subgroup. The HOMA-IR index, taken as a measure of
insulin resistance, was significantly enhanced in HI sub-
jects when compared to the LS and NI subgroups (Figure 1).
Reciprocally, the QUICKI index, a measure of insulin
sensitivity, was significantly decreased in HI obese
subjects when compared with LS and NI volunteers
(P < 0.0001) (Figure 3C).
Cytokines and inflammatory response
Circulating concentrations of TNF-α, IL-6 and C-
reactive protein, measured in basal period, are presented
in Table 3. The present study showed a striking inflamma-
tory difference between evaluated lean and obese ex-
perimental groups, being significantly greater in obese
subjects when compared to the control (Figure 4)
Table 2 The table shows the serum parameter analyses to triglyceride, cholesterol, high-density (HDL), low-density
(LDL) and very-low density (VLDL) cholesterol, uric and free fat acids plasma levels from the lean (LS) group, compared
with the obese subgroup subjects
Control n Norminsulinemic n Hyperinsulinemic n P P1 P2 P3
(LS) (NI) (HI) LS vs. NI LS vs. HI NI vs. HI
Cholesterol (mg/dl) 169.33 ± 40.08 12 186.64 ± 27.07 14 184.55 ± 15.97 11 ns 0.045 ns ns
HDL-cholesterol (mg/dl) 35.08 ± 13.31 13 26.50 ± 4.64 14 26.73 ± 8 11 ns ns ns ns
LDL-cholesterol (mg/dl) 113.17 ± 32.31 12 133.67 ± 27.39 15 139.83 ± 24.56 12 0.040 ns 0.015 ns
VLDL-cholesterol (mg/dl) 18.92 ± 6.99 12 21.87 ± 10.28 15 22.91 ± 8.3 11 ns ns ns ns
Triglyceride (mg/dl) 94.92 ± 34.45 12 111.00 ± 50.13 15 114.91 ± 41.06 11 ns ns ns ns
Uric acid (mg/dl) 4.75 ± 1.53 13 4.49 ± 0.89 15 5.25 ± 1.07 11 ns ns ns 0.033
Free fatty acids (mg/dl) 382.05 ± 129.80 12 545.11 ± 454.67 14 396.58 ± 97.1 12 ns ns ns ns
Values are means ± DP; P values for comparison between groups by non-parametric analysis of Kruskal Wallis; P, comparing all groups and P1, P2 and P3 comparison
between groups.
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period (Table 3; Figure 4D), was significantly enhanced
in NI subjects when compared to HI groups (P < 0.04).
As presented in Figure 4, the obeses subjects showed
an expressive and significant increase of IL-6 (Figure 4A),
TNF-α (Figure 4B) and C-reactive protein (Figure 4C)
plasma levels compared with the LS group. No difference
in leptin plasma level was observed in HI and NI sub-
groups (Table 3).
Renal function data
The data for renal function of both LS and OS, before
and after oral glucose load, are summarized in Figure 5.
The urinary flow rates (Figure 5B) did not significantly
differ among the groups during the renal tubule sodium
handling studies, except after 120 min of glucose load in
HI subgroup. The glomerular filtration rate (Figure 5A),Figure 2 Graphic representation of arterial systolic and diastolic
blood pressure in control lean (LS, n = 13) subjects compared to
normoinsulinemic (NI, n = 15) and hyperinsulinemic (HI, n = 10)
volunteer subgroups. Results are expressed as mean ± SD. The level
of significance was set at *P≤ 0.05 or **P≤ 0.01 (non-parametric
analysis by Kruskal-Wallis test).estimated by CCr, before and after oral glucose load and,
consequently, the calculated glomerular filtered load was
unchanged in obese subgroups when compared to age-
matched LS subjects. The study shows a significant de-
crease of the FENa after oral glucose ingestion in LS
(1.74 ± 0.17% vs. 1.32 ± 0.12%, P = 0.0318, n = 10) and
normoinsulinemic (HI: 1.63 ± 0.18% vs. HI + OG: 1.19 ±
0.13%, P = 0.0283, n = 14) but not in hyperinsulinemic
obese subgroup (HI: 1.66 ± 0.20% vs. 1.36 ± 0.15%, P =
0.1344, n = 12) (Figure 5C). The decreased FENa was ac-
companied by significant fall of the FEPPNa (Figure 5D)
in LS (LS: 9.41 ± 0.68% vs. 6.38 ± 0.92%, P = 0.086), nor-
moinsulinemic (NI: 8.41 ± 0.72% vs. 5.66 ± 0.53%, P =
0.0025) and hyperinsulinemic subjects (HI: 8.82 ± 0.98%
vs. 6.32 ± 0.67%, P = 0.0264) without any change in prox-
imal fractional sodium excretion (FEPNa, Figure 5E).
This expressive decrease in FEPPNa and FENa produced
by oral glucose intake was followed by significant de-
crease in kaliuresis (Figure 5F) in the all experimental
groups. The experimental groups (LS: 1.24 ± 0.62 or
obeses NI: 1.02 ± 0.42 and HI: 1.07 ± 0.35) did not
showed significant changes in urinary protein excretion
(in mg/dl).
Interaction analysis
Figure 6 shows the interaction between independent fac-
tors related to systolic blood pressure, body constitution
and estimating HOMA-IR index values with multiple
linear regression analysis. The data confirms a positive
and significant high correlation between basal fasting in-
sulin plasma level, HOMA-IR index, fat body mass and
systolic blood pressure (P < 0.001). Despite a high in-
flammatory activity in both of obese subgroups was not
observed any significant correlation between inflamma-
tory markers serum levels and the reduction in all of the
studied groups. However, a significant negative Pearson
correlation was observed between increased HOMA-IR
index and adiponectin plasma levels (R2 = 0.123, P <
Figure 3 Graphic representation depicts the total area under curve to glucose (panel A) and insulin (panel B) serum levels after oral
glucose test to control lean (LS, n = 12) subjects compared to normoinsulinemic (NI, n = 14) and hyperinsulinemic (HI, n = 12) volunteer
subgroups. Also shows the estimating of quantitative insulin-sensitivity check (QUICKI) index (panel C) values for lean and obese subjects. Results
are expressed as mean ± SD. The level of significance was set at *P ≤ 0.05 or **P ≤ 0.01 (non-parametric analysis by Kruskal-Wallis test).
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cretion and adiponectin levels (R2 = 0.395, P < 0.013, n =
32).
Discussion
More and more evidence is emerging that highlights the
far-reaching consequences of obesity on kidney morph-
ology and function disorders. The prevalence of obesity
is increasing by alarming proportions worldwide and more
than 20% of the world population is overweight, while
nearly 300 million are obese [22-24]. Driving forces for
overweight and obesity include increasing sedentary life-
style and consumption of a western diet high in fat,
fructose and salt and their interaction with genetic fac-
tors and epigenetic processes [25-27]. This study shows
that a hyperinsulinemic (HI: 10.85 ± 4.09 μg/ml) subgroupTable 3 The table shows the circulating plasma concentration
period in obese and lean subjects
Control n Normoinsulinemic n
(LS) (NI)
TNF-α (pg/ml) 1.62 ± 0.40 12 2.13 ± 0.60 15
IL-6 (pg/ml) 0.90 ± 0.38 12 1.97 ± 1.10 15
CRP (mg/l) 1.56 ± 2.25 12 5.56 ± 4.89 15
Adiponectin (μg/ml) 7.64 ± 2.94 12 8.91 ± 3.39 15
Leptin (μg/ml) 11.99 ± 10.63 12 40.70 ± 21.54 15
TNF-α - tumor necrosis factor-alpha; IL-6 – interleukin 6; CRP – C reactive protein; V
parametric analysis of Kruskal Wallis; P, comparing all groups: P1, P2 and P3 compariof well-characterized metabolic syndrome bearers-obese
subject but not all obese subjects, show higher glycemic
and elevated blood pressure levels when compared to lean
(LS) and meanly, normoinsulinemic (NI: 5.51 ± 1.18 μg/
ml, P < 0.027) groups. Here, it has been supposed that in-
sulin resistance may result from a cluster of inflammatory
and metabolic disorders with an inherent potential for
hemodynamic abnormalities particularly, higher blood
pressure. Also in the current study, the combination
of hyperinsulinemia, higher HOMA-IR (HI: 2.19 ± 0.70
(n = 12) vs. LS: 0.83 ± 0.23 (n = 12) and NI: 0.98 ± 0.22
(n = 15), P < 0.0001) associated with lower QUICKI
in HI obese when compared with LS and NI volunteers
(P < 0.0001), strongly suggests the occurrence of insulin
resistance and, as previously demonstrated, a defect in
insulin-stimulated peripheral action [28-30]. The links of TNF-α, IL-6 and C-reactive protein, measured in basal
Hyperinsulinemic n P P1 P2 P3
(HI) LS vs. NI LS vs. HI NI vs. HI
2.01 ± 0.51 12 0.012 0.005 0.028 ns
1.95 ± 0.96 12 0.001 0.001 0.001 ns
6.37 ± 6.70 12 0.025 0.006 ns ns
6.32 ± 2.49 12 ns ns ns 0.040
33.51 ± 21.82 12 0.006 0.002 0.018 ns
alues are means ± DP; P values for comparison between groups by non-
son between groups.
Figure 4 Graphic representation depicts the circulating plasma concentrations of IL-6 (Panel A), TNF-α (Panel B), and C-reactive protein
(Panel C) and Adiponectin (Panel D), measured in basal period to control lean (LS, n = 12) subjects compared to normoinsulinemic
(NI, n = 15) and hyperinsulinemic (HI, n = 12) volunteer subgroups. Results are expressed as mean ± SD. The level of significance was set at
* P ≤ 0.05 or ** P≤ 0.01 (non-parametric analysis by Kruskal-Wallis test).
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scribed above does not prove the presence of causal rela-
tionships, but experimental findings have shown possible
mechanisms, which may account for a putative relation-
ship [31,32]. Otherwise, the prevalence of hypertension in
type 2 diabetes mellitus is increased 3-fold, and the coex-
istence of hypertension in diabetic patients greatly en-
hances the development of cardiovascular disease and
chronic renal failure [31]. The current study shows, al-
though on normal range, a clear and significant increase
of the arterial pressure in hyperinsulinemic obeses, char-
acterizing a prehypertension state. Prehypertension is in-
creasingly recognized as a risk factor for cardiovascular
disease. This is supported by studies demonstrating the
association of increased systolic or diastolic dysfunction in
a prehypertension state in genetic or diet-induced rodent
models of obesity [8-10]. It is estimated that 37% of the
adult population has prehypertension and 40% of these
subjects will progress to hypertension within a two-year
time frame [8]. By the way, impaired insulin stimulated
uptake of glucose associated with impaired vasodilatation
has been shown to be early manifestations in insulin re-
sistant models of obesity [11-13,24]. In this respect, in-
creased activation of renin-angiotensin system (RAS) and
enhanced oxidative stress within cardiovascular tissue in
obesity are important mediators of insulin resistance and
vasoconstriction [33]. Although the precise mechanism by
which arterial blood pressure enhances in HI obese sub-
jects remain to be elucidated, taking in account our andprevious findings we may suppose that systemic inflam-
matory response, endothelial dysfunction, sympathetic
neural and renin-angiotensin overactivity and, renal fluid
and electrolyte balance disorder is thought to play a dom-
inant role in the long-term salt and water retention, vascu-
lar resistance and consequently, enhanced blood pressure.
In the past two decades, the view of adipose tissue has
gone from revolutionary change from inert energy store
to the biggest endocrine organ [34]. The current study
confirms that in the obese state, the plasma levels of lep-
tin, TNF-α, IL-6 and PCR are increased, and these mole-
cules have been shown to be associated with metabolic
inflammation or neologically by metaflammation to re-
view see [35,36] and insulin resistance. Although mecha-
nisms underlying this inflammatory response are not
well understood, endoplasmic reticular stress is one of
the cellular stress events that activate inflammatory sig-
naling pathways including activation of JNK and mTOR
[35,36]. Also, have been shown that TNF-α and IL-6
cause systemic insulin resistance through activation of
MAP kinases, protein kinase C (PKC) and SOCS-3
mediated proteasome degradation [24]. In addition to
adipose tissue dysfunction, activation of Toll-like re-
ceptor 4 (TLR-4) and perhaps other TLRs induced by
nutrients excess such as saturated fatty acid, gut de-
rived lipopolysaccharide (LPS), uric acid and/or intes-
tinal dysbiosis contributes significantly to hepatic and
systemic inflammatory response in hyperinsulinemic
obeses [37,38].
Figure 5 Bar graph of Creatinine clearance (CCr) (Panel A), Urinary flow (Panel B), fractional sodium excretion (FENa) (Panel C),
proximal (FEPNa) (Panel E) and post-proximal (FEPPNa) (Panel D) fractional sodium excretion and fractional potassium excretion (FEK)
(Panel F) in LS and NI and HI obese subjects before and after oral glucose load (OG). See Results for statistical analysis details. The data are
reported as the means ± SD. The level of significance was set at *P ≤ 0.05 or **P ≤ 0.01 to compare LS vs. LS + OG, NI vs. NI + OG and HI vs. HI + OG
subgroups (non-parametric analysis by Kruskal-Wallis test).
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ponectin. Here, the adiponectin measured in basal
period was significantly enhanced in NI subjects when
compared to HI groups (P < 0.04). The association be-
tween adiponectin and hypertension is evident in clinical
studies by showing that hypoadiponectinemia is a risk
factor for hypertension independent of insulin resistance
and diabetes, while overexpression of adiponectin may
also decrease the blood pressure in genetically obese
mice [39-41]. Nevertheless, despite the well-established
association of adiponectin with metabolic disorders and
hypertension, very few studies address the relationship
between adiponectin and hypertension at a mechanistic
level. Recently, several studies have also focused on the ef-
fects of adiponectin on the sympathetic nervous system
(SNS), RAS and kidney function. The role of increased
SNS activity in insulin resistance and hypertension is in-
creasingly recognized [15,24,31,42]. A disproportionate ac-
tivation of SNS in the obese state is proposed to play
important roles in obesity-associated metabolic dysfunc-
tion [43]. Conversely, Tanida et al. [44] have found thatadiponectin attenuates blood pressure and sympathetic
nerve activity by inhibition of leptin action in the brain.
Taking in account our and the above findings, we may
speculate that adiponectin, secreted from adipose tissue
decreases the risk for insulin resistance, inflammation, and
blood pressure elevation in a particular subgroup of nor-
moinsulinemic obeses (Figure 6).
Surprisingly, the current report shows a similar insulin-
mediated reduction of post-proximal urinary sodium ex-
cretion in lean (LS: 9.41 ± 0.68% vs. 6.38 ± 0.92%, P =
0.086) and normoinsulinemic (NI: 8.41 ± 0.72% vs. 5.66 ±
0.53%, P = 0.0025) and hyperinsulinemic obese subjects
despite of persistent and pronounced insulin plasma levels
in HI obese subgroup (HI: 8.82 ± 0.98% vs. 6.32 ± 0.67%,
P = 0.0264), after oral glucose load, despite elevated insuli-
nemic levels in hyperinsulinemic obeses. This exaggerated
enhancement of serum insulin levels in response to an
oral glucose load, associated with similar renal sodium re-
absorption in NI and HI subjects, separately, could not be
enough to explain the high blood pressure development in
our specific HI obese subgroup. Thus, the present findings
Figure 6 Graphic representation depicts whole lean and obese subject’s data interaction between independent factors related to
whole systolic blood pressure (Panel B and C), body constitution (Panel C and E) and estimating HOMA-IR (Panel A, D and E) index
values with multiple linear regression analysis.
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function during high blood pressure development in obese
subjects, beyond of those involved in the renal sodium
transport. Furthermore, the equal tubule sodium re-
absorption in normoinsulinemic and hyperinsulinemic
obeses observed in the current study may argue favorably
to decrease renal insulin sensitivity in HI volunteers. The
sodium-retaining effect of insulin has been known for a
long time [15], but there is no consensus on the exact
mechanism of action. Prior studies assume that antina-
triuretic effect of insulin, predominantly in the post-
proximal renal tubules [15,45], may be due to a fall in
filtration fraction, renal sympathetic nerve and/or RAS
overstimulation and, suppression of natriuretic peptide re-
lease [46]. Also, for all of experimental groups, the contribu-
tion of the glucose filtered load to tubule Na+ reabsorption
via a Na+/glucose cotransport or Na+/H exchanger should
also be considered. Here, the oral glucose load in LS and OS
did not change the glomerular filtration rate, estimated by
CCr and consequently, the filtered sodium load, sug-
gesting that the antinatriuresis observed was mediated
by direct tubular mechanisms. Our data was positively
related with an increased post-proximal fractional re-
absorption of sodium without enhanced tubular potassium
excretion suggesting that insulin action preceded the distal
segments of nephron.
Although the renin-angiotensin system (RAS) was not
detailed here, the angiotensin II (AngII) effects on sym-
pathetic activation are widely demonstrated by severalstudies. Under pathophysiological conditions, such as
obesity-associated metabolic diseases, the overproduc-
tion of AngII plays an important role in the development
and progression of insulin resistance, hyperinsulinemia
and arterial hypertension. The RAS causes sustained
sympathetic overactivity by modulating central neurons
in the subfornical organ of the forebrain [47,48]. Inter-
estingly, these neural responses are associated with modu-
lation of peripheral T cell immune responses [47,48]
suggesting a link between glucose metabolic disorders and
the central regulation of systemic immune and/or inflam-
matory responses through brain AngII signaling and re-
sultant increased SNS outflow. Thus, we may hypothesize
that inappropriate activation of RAS and/or SNS may sig-
nificantly contribute to this inflammatory response, pro-
gression of insulin resistance and kidney disorders in this
specific subgroup of hyperinsulinemic obese. We also may
not rule out the participation of adiponectin in this
process since the plasma adiponectin level is reported
to be increased and to show a positive correlation with
plasma natriuretic factors in heart disorders (7,14). The
current study has shown that the plasma adiponectin
level was positively correlated with the enhanced natri-
uresis in normoinsulinemic obese subjects while it is de-
creased in HI subgroup. The plasma natriuretic peptide
level had the same influence on adiponectin as that of the
waist circumference, HDL-cholesterol, and triglycerides.
We suppose that positive association between plasma adi-
ponectin and normoinsulinemic individuals in our study
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and so, may predict a better prognosis or morbidity of car-
diovascular disease, specifically on hypertension develop-
ment, even in obese subjects. The precise mechanism of
these phenomena remains unknown.
Conclusion
In conclusion, this study highlight the importance of
dysfunctional inflammatory modulation associated with
metabolic disorders (hyperinsulinemia and peripheral in-
sulin resistance), high blood pressure, and renal dysfunc-
tion in a particular subgroup of obeses. Supposedly, these
metabolic and blood pressure abnormalities are striking
attenuate by enhanced adiponectin plasma levels in HI
subjects compared to LS and NI subjects. The findings
of current study may also state that a maladaptive in-
flammatory response seems to be central to obese-
associated cardiovascular disorder and insulin resist-
ance. Prospective investigations are therefore warranted
to determine whether high adiponectin levels are related
to better prognosis or future morbidity of metabolic or
kidney disorders even in obese subjects.
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